CU23823A3 - Agonistas y antagonistas completos y parciales altamente potentes del receptor nociceptina/orfanina fq - Google Patents

Agonistas y antagonistas completos y parciales altamente potentes del receptor nociceptina/orfanina fq

Info

Publication number
CU23823A3
CU23823A3 CU20070195A CU20070195A CU23823A3 CU 23823 A3 CU23823 A3 CU 23823A3 CU 20070195 A CU20070195 A CU 20070195A CU 20070195 A CU20070195 A CU 20070195A CU 23823 A3 CU23823 A3 CU 23823A3
Authority
CU
Cuba
Prior art keywords
nociceptine
orphanine
partials
receiver
complete
Prior art date
Application number
CU20070195A
Other languages
English (en)
Inventor
Domenico Regoli
Girolamo Calo
Severo Salvadori
Remo Guerrini
Original Assignee
Ufpeptides S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ufpeptides S R L filed Critical Ufpeptides S R L
Publication of CU23823A3 publication Critical patent/CU23823A3/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)

Abstract

La presenta invención describe análogos de péptido de nociceptina/orfanina FQ, composiciones de los mismos para el tretamiento de trastornos y disfunciones relacionadas con la activación o bloqueo de receptores NOP.
CU20070195A 2005-02-15 2007-08-13 Agonistas y antagonistas completos y parciales altamente potentes del receptor nociceptina/orfanina fq CU23823A3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000003A ITFE20050003A1 (it) 2005-02-15 2005-02-15 Agonisti pieni e parziali ed antagonisti del recettore per nocicettina/orfanina fq ad elevata potenza.

Publications (1)

Publication Number Publication Date
CU23823A3 true CU23823A3 (es) 2012-06-21

Family

ID=36685750

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20070195A CU23823A3 (es) 2005-02-15 2007-08-13 Agonistas y antagonistas completos y parciales altamente potentes del receptor nociceptina/orfanina fq

Country Status (29)

Country Link
US (1) US8227414B2 (es)
EP (1) EP1851241B1 (es)
JP (1) JP5281292B2 (es)
KR (1) KR101294895B1 (es)
CN (2) CN104689293A (es)
AU (1) AU2006215639B2 (es)
BR (1) BRPI0606998B8 (es)
CA (1) CA2598121C (es)
CR (1) CR9379A (es)
CU (1) CU23823A3 (es)
CY (1) CY1116456T1 (es)
DK (1) DK1851241T3 (es)
EA (1) EA011325B1 (es)
ES (1) ES2541308T3 (es)
HR (1) HRP20150731T1 (es)
HU (1) HUE025000T2 (es)
IL (1) IL185235A (es)
IT (1) ITFE20050003A1 (es)
MA (1) MA29288B1 (es)
MX (1) MX2007009523A (es)
NI (1) NI200700205A (es)
NO (1) NO341856B1 (es)
PL (1) PL1851241T3 (es)
PT (1) PT1851241E (es)
RS (1) RS54095B1 (es)
SI (1) SI1851241T1 (es)
UA (1) UA91844C2 (es)
WO (1) WO2006087340A2 (es)
ZA (1) ZA200707714B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITNA20090026A1 (it) * 2009-05-14 2010-11-15 Agostino Bruno D Agonisti del recettore nop e loro usi terapeutici
CN112730849B (zh) * 2021-01-14 2023-03-10 山西医科大学第二医院 内源性孤啡肽作为糖尿病合并无症状性心肌缺血的血清生物标志物的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2348604T3 (es) 2002-04-29 2010-12-09 Euro-Celtique S.A. Péptidos conformacionalmente restringidos que se unen al receptor orl-1.
ITMI20022022A1 (it) * 2002-09-24 2004-03-25 Girolamo Calo' Analoghi di nocicettina.
ITMI20031349A1 (it) * 2003-07-01 2005-01-02 Ufpeptides S R L Antagonisti del recettore nop e loro usi terapeutici.
CN1634980A (zh) * 2004-10-10 2005-07-06 兰州大学 孤啡肽的类似物

Also Published As

Publication number Publication date
KR101294895B1 (ko) 2013-08-08
HUE025000T2 (en) 2016-01-28
SI1851241T1 (sl) 2015-08-31
WO2006087340A3 (en) 2006-10-26
UA91844C2 (ru) 2010-09-10
BRPI0606998A2 (pt) 2014-01-21
EP1851241A2 (en) 2007-11-07
AU2006215639B2 (en) 2011-05-26
US20100273710A1 (en) 2010-10-28
WO2006087340A2 (en) 2006-08-24
EA200701732A1 (ru) 2008-02-28
PL1851241T3 (pl) 2015-09-30
CA2598121C (en) 2014-11-25
WO2006087340A8 (en) 2007-06-21
CR9379A (es) 2008-04-25
BRPI0606998B8 (pt) 2021-05-25
CN104689293A (zh) 2015-06-10
US8227414B2 (en) 2012-07-24
IL185235A (en) 2014-08-31
JP2008530058A (ja) 2008-08-07
EA011325B1 (ru) 2009-02-27
RS54095B1 (en) 2015-10-30
EP1851241B1 (en) 2015-04-08
KR20070119614A (ko) 2007-12-20
CA2598121A1 (en) 2006-08-24
IL185235A0 (en) 2008-02-09
HRP20150731T1 (hr) 2015-08-14
BRPI0606998B1 (pt) 2018-04-10
DK1851241T3 (en) 2015-06-29
ZA200707714B (en) 2008-06-25
ES2541308T3 (es) 2015-07-17
NO341856B1 (no) 2018-02-12
CN101128482A (zh) 2008-02-20
MX2007009523A (es) 2007-09-07
AU2006215639A1 (en) 2006-08-24
PT1851241E (pt) 2015-08-28
MA29288B1 (fr) 2008-02-01
CY1116456T1 (el) 2017-03-15
NO20074702L (no) 2007-10-29
ITFE20050003A1 (it) 2006-08-16
NI200700205A (es) 2008-06-17
JP5281292B2 (ja) 2013-09-04

Similar Documents

Publication Publication Date Title
GT200600453A (es) Indoles de acilo, composiciones que contienen dichos compuestos y procedimientos de uso
CO6361994A2 (es) Antagonistas del receptor de orexina de isonicotinamida
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
GT200800198A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide del tipo 1.
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
CY1110882T1 (el) Ανταγωνιστες υποδοχεων ορεξινης υποκατεστημενης διαζεπανης
CL2011002942A1 (es) Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2013003816A1 (es) Compuestos derivados de carboxamida y urea que comprende pirazol aromatico sustituido, ligantes del receptor de vanilloide; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o profilaxis del dolor, migraña, enfermedad de parkinson, trastornos gastrointestinales, osteoporosis, entre otras enfermedades.
CL2012001722A1 (es) Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes.
RS63204A (en) Substituted quinazolin-4-ylamine analogues as modulators of capsaicin
DE602007012072D1 (de) Orantagonisten
CL2011003147A1 (es) Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer.
CL2011000662A1 (es) Compuestos derivados de n-heteroaril-sulfonil-amida, moduladores selectivos del receptor cb2; composicion farmaceutica; y uso para el tratamiento del dolor, enfermedad pulmonar,enfermedad autoinmune, enfermedad neurologica, entre otras.
CL2006003737A1 (es) Uso de compuestos derivados de triazina o pirimidina sustituida, para tratar o prevenir enfermedades mediadas por los receptores de prokineticina 2 tales como trastornos gastrointestinales.
ECSP088584A (es) Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl)
ATE474834T1 (de) Als agonisten des gpr38-rezeptors geeignete biarylverbindungen
CL2011002467A1 (es) Compuestos derivados de 6-(3-aza-biciclo[3.1.0]hex-3-il)-2-fenilpirimidinas, antagonistas del receptor p2y 12; composicion farmaceutica que los comprende; y su uso en el tratamiento de trastornos oclusivos. pct fase nacional.
CL2004000868A1 (es) Compuestos derivados de acidos carboxilicos, antagonistas del receptor de calcio 8casr); composiciones farmaceuticas que comprenden el compuesto, utiles para el tratamiento de osteoporosis.
CR11562A (es) Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina
CR20110202A (es) Antagonistas de la via hedgehog de ftalazina disustituida
ATE519498T1 (de) Kombination aus somatostatin-analoga unterschiedlicher selektivität für humane somatostatin-rezeptor-subtypen
CL2008000091A1 (es) Compuestos derivados de piridina, inhibidores del receptor p2y12; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento del trastorno de agregacion plaquetaria.
SV2008002653A (es) Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
ATE487481T1 (de) N-(4-oxo-3,4-dihydrochinazolin-2-yl)butanamide als androgenrezeptormodulatoren
CL2007003503A1 (es) Compuestos derivados de indol-2-il-carbonil-piperidina-benzoimidazolona y de indol-2-il-carbonil-piperidina-benzoxazolona, antagonistas del receptor de la v1a; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de dismenorrea

Legal Events

Date Code Title Description
FG Grant of patent